Overview

A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
0
Participant gender:
All
Summary
It is estimated that in the United States there are approximately 8 million individuals with moderate to severe chronic kidney disease (CKD), not on dialysis. Volume expansion plays an important role in the pathogenesis of hypertension in patients with CKD. For this pilot study, the investigators hypothesize that administration of chlorthalidone among patients with moderate to severe CKD will improve blood pressure (BP).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Indiana University
Treatments:
Chlorthalidone
Criteria
Inclusion Criteria:

- Age greater than 18 years.

- Estimated glomerular filtration rate (eGFR) ≤ 45 ml/min/1.73m2 but ≥20 mL/min/1.73m2.

- Poorly controlled blood pressure by 24-hour ambulatory blood pressure (BP) monitoring.

- Treated hypertension: use of at least one antihypertensive drug. One of the drugs
should be either an angiotensin converting enzyme (ACE) inhibitor or angiotensin
receptor blocker (ARB). If these are contraindicated then use of a beta-blocker is
required.

Exclusion Criteria:

- Use of thiazide or thiazide-like drugs in the previous 3 months.

- Use of furosemide in a dose >200 mg/d.

- Ambulatory BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP
monitoring.

- Expected to receive renal replacement therapy within the next 3 months.

- Vascular event such as myocardial infarction, heart failure hospitalization, or stroke
within 3 months prior to randomization.

- Pregnant or breastfeeding women or women who are planning to become pregnant or those
not using a reliable form of contraception (oral contraceptives. condoms and
diaphragms will be considered reliable).

- Known hypersensitivity to thiazide or sulfa drugs.

- Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled
corticosteroids will be permitted.